Consensus Report on Shigella Controlled Human Infection Model: Conduct of Studies
Date
2019Journal
Clinical infectious diseasesPublisher
Oxford University PressType
Article
Metadata
Show full item recordAbstract
Shigella causes morbidity and mortality worldwide, primarily affecting young children living in low-resource settings. It is also of great concern due to increasing antibiotic resistance, and is a priority organism for the World Health Organization. A Shigella vaccine would decrease the morbidity and mortality associated with shigellosis, improve child health, and decrease the need for antibiotics. Controlled human infection models (CHIMs) are useful tools in vaccine evaluation for early up- or down-selection of vaccine candidates and potentially useful in support of licensure. Over time, the methods employed in these models have become more uniform across sites performing CHIM trials, although some differences in conduct persist. In November 2017, a Shigella CHIM workshop was convened in Washington, District of Columbia. Investigators met to discuss multiple aspects of these studies, including study procedures, clinical and immunological endpoints, and shared experiences. This article serves as a uniform procedure by which to conduct Shigella CHIM studies. Copyright The Author(s) 2019.Sponsors
This supplement is sponsored by the Bill & Melinda Gates Foundation.Identifier to cite or link to this item
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85076303359&doi=10.1093%2fcid%2fciz892&partnerID=40&md5=4b46eafc3640abf66abf8326a266840f; http://hdl.handle.net/10713/11536ae974a485f413a2113503eed53cd6c53
10.1093/cid/ciz892
Scopus Count
Collections
Related articles
- Consensus Report on Shigella Controlled Human Infection Model: Introduction and Overview.
- Authors: MacLennan CA, Aguilar AO, Steele AD
- Issue date: 2019 Dec 9
- Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays.
- Authors: Kaminski RW, Pasetti MF, Aguilar AO, Clarkson KA, Rijpkema S, Bourgeois AL, Cohen D, Feavers I, MacLennan CA
- Issue date: 2019 Dec 9
- Consensus Report on Shigella Controlled Human Infection Model: Clinical Endpoints.
- Authors: MacLennan CA, Riddle MS, Chen WH, Talaat KR, Jain V, Bourgeois AL, Frenck R, Kotloff K, Porter CK
- Issue date: 2019 Dec 9
- How can controlled human infection models accelerate clinical development and policy pathways for vaccines against Shigella?
- Authors: Giersing BK, Porter CK, Kotloff K, Neels P, Cravioto A, MacLennan CA
- Issue date: 2019 Aug 7
- Developing and utilizing controlled human models of infection.
- Authors: Porter CK, Louis Bourgeois A, Frenck RW, Prouty M, Maier N, Riddle MS
- Issue date: 2017 Dec 14